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Background: Over expression of C-erbB-2 a Human epidermal growth factor has been reported 
in several human carcinomas including prostate cancer. In prostate cancer studies have for it to 
have a prognostic role and to predict likelihood of resistance in hormonal therapy. The 
oncoprotein receptors are now being looked at as possibility of prognostic predictor at the same 
time as a target for therapy in cancers. 
Objective: To determine the prevalence of over expression of C-erbB-2 oncoprotein receptor 
using Immunohistochemistry in Mulago Hospital. 
Material and Methods: Biopsy samples were taken from patients suspected to have prostate 
cancer convectional histology (Hand E) done. The tumours in the Confirmed slides were then 
graded as well differentiated, moderately differentiated and poorly differentiated. 
Immunohistochemistry staining was done using avidin-biotin method. To standardize the 
staining, the manufacturer (DAKO) supplied both positive and negative control. A well defined 
scoring system based upon the number of C-erbB-2 on the cell surface was applied. The score 
ranges from score 0 to +3, over expression is defined as score equal or greater than +2. 
Results: over expression was seen in 18 out of 40 cases. Stastistically there was no association 
between histological grades and over expression. But most of the patients that over expressed C-
erbB-2 were either moderately differentiated or poorly differentiate 14 of the 18 positive cases. 
Conclusion and Recommendation: Immunohistochemistry which is cheap and easy to use can 
be used in our setting to analyse the level of C-erbB-2.  
Its important that long term follow up of the patients with over expression is needed to further 




C-erbB-2 Oncoprotein is a 185-KDa 
glycoprotein, often simply called C-erbB-
2oncoprotein receptor. The C-erbB-2 
oncoprotein is encoded by the human 
epidermal growth factor receptor -2 (HER-2 
orC-erbB-2) proto-oncogene C-erbB-2 is 
one of the best studied factor receptor 
systems. The erbB or type 1-tyrosine kinase 
factor family compromises of four 
homologous epidermal growth factor 
receptors: erbB-2, erbB-3 and erbB-4.1  The 
erbB family plays an important role in 
regulating cell growth, survival and 
differentiation in a complex manner. The 
erbB-2 is the preferred heterodimerisation 
partner within the family and can be 
stabilised and transactivated in heterodimers 
by ligands for the partner erbB monomer, 
such as erbB-1or erbB-2 and erbB-4.2 This 
heterodimerisation between erbB-2 and 
other receptor of the family allows for its 
participation in signal transduction even in 
the absence of a cognate ligand. Infarct 
erbB-2 tends to show particularly high 
signalling potency which may explain its 
significant role in oncogenic phenotype3,4. 
 
In vitro animal studies have indicated that 
the erbB-2 gene amplification and 
oncoprotein over expression play a pivotal 
role in oncogenic transformation, 
tumorigenesis and metastasis.5 The normal 
epithelial cell possess two copies of C-erbB-
2 gene and expresses low level of C-erbB-2 
oncoprotein receptors on the cell surface 
this is equivalent to some tens of thousands 
of receptors per cell. With oncogenic 
transformation C-erbB-2 gene amplification 
generates more than the normal gene copies 
leading to 10-100 fold increase in erbB-2 
monomers on the cell surface on the cell 
surface6. The expression of the C-erbB-2 
oncogene and presence of the epidermal 
growth factor are becoming increasingly 
important as prognostic parameters in 
addition to standard histological and clinical 
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evaluation of patients with carcinomas. 
Over expression of the C-erbB-2 oncogene 
products has been identified in 
adenocarcinomas of breast, ovaries, colon, 
and lung and it’s linked to poor prognosis in 
a subset of patients with cancer of the breast 
and correlates with shorter survivor but not 
with disease free intervals7. 
 
C-erbB-2 and prostate cancer: Oncoprotein 
amplification are frequently found in solid 
tumours and often associated with 
aggressive growth. This combined with the 
recent advance in the early detection of 
prostate cancer has stimulated the interest in 
the development of techniques for 
determining metastatic potential and 
prognostic factors. The over expression of 
C-erbB-2 is present in 70%to 80% of 
prostate cancer patients8. 
 
Koeppen et al9 in a retrospective survey of 
C-erbB-2 over expression in solid tumours 
by  standardised immunohistochemical 
assay, found over expression of C-erbB-2 
oncoprotein in 15 of  61(24.6%) of prostate 
cancer cases. The prognostic role of  C-
erbB-2 oncoprotein has been noted in many 
studies. Visakorpi at el al10. found variable 
immunoreactivity in prostate cancer tissues. 
The patients with over expression had 
locally more advanced disease, higher 
histological grade, and a worse 10-year 
survival than those with C-erbB-2 negative 
carcinomas. The tumours with C-erbB-
2positivily had two to three times higher S-
phase fractions suggesting that C-erbB-
2over expression confers proliferative 
advantage, by including secondary changes 
which are responsible for the acquisition of 
tumorigenic and metastatic prostate tissue. 
Sadasivan et al11 using a monoclonal 
antibody and IHC method, nine out of 25 
case of adenocarcinomas showed over 
expression on flow cytometric analysis 
corrected with higher histological grade, 
higher stage of disease and  higher phase 
and aneuploidy, suggesting C-erbB-2 to be a 
prognostic marker. 
 
Kuhn et al12 in a prospective study with 
53patients with carcinoma of the prostate 
using IHC found definite positive staining in 
18 of 53 (34%) cases of prostate cancer. 
There was significant association between 
C-erbB-2 oncoprotein status and 
histological grades with(P=0.03). On 
following the patients for three years he 
found positive staining as the disease 
progressed in those who were previously 
negative. 
 
A retrospective study using paraffin 
embedded specimens on 124 localised 
prostate cancer patients who had no 
involvement of seminal vesicle or lymph 
node was done by Veltri et al patients were 
divided as a progressors and non-
progressors using PSA level as an indication 
of recurrence (mean follow up of =8.6+/- 
1.8 years). The status of C-erbB-2 was 
significant in detecting progression 
(P=0.0015)13. 
 
Meanwhile Morote et al14 using 
Immunohistochemistry, studied over 
expression of C-erbB-2 in primary prostatic 
tissues of 70 patients with metastatic 
disease. Positive staining was present in 
64.3%. No signicant relation was observed 
between histological grade and C-erbB-2 
over expression or severity of the disease 
based on extent of metastasis. But the 
average specific survival in patients with C-
erbB-2 over expression was less than in 
those withC-erbB-2 negativity with 
(P=0.034).from the results they suggested 
that over expression of C-erbB-2 
oncoprotein would be considered as an 
independent prognostic factor of metastatic 
prostate cancer14. 
 
Development of androgen therapy resistant 
prostate cancer in many patients, for who 
therapeutic options remains limited, has led 
researchers to focus attention on 
understanding the molecular genetics of 
prostate cancer. Such analysis may lead to 
identification of relevant new prognostic 
and therapeutic indicators. The recent 
demonstration that a monoclonal anti 
C_erbB-2 anti bodies (Herceptine) used in 
combination with chemotherapy is effective 
as first line treatment for women who have 
C-erbB-2 positive metastatic breast cancer. 
This has prompted investigators to evaluate 
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combination of chemotherapy and 
Herceptine in hormone refractory prostate 
cancer15. The aim of this study was to 
determine the status of C-erbB-2 
oncoprotein among patients with carcinoma 
of the prostate attending Mulago Hospital 
using Immunohistochemistry. 
Materials and Methods 
 
The avidin-biotin methods were used to 
stain for C-erbB-2. Sections were treated 
with antigen retrieval solution PH 6.1 
(51700) in micro over for 10 minutes to 
improve antigenicity. The primary antibody 
was rabbit polyclonal antibodies (DAKO 
A485) at diluting of 1:20.  The primary 
antibodies was incubated at 370C for one 
hour and subsequent  incubations were done 
at room temperature After gentle washes 
with three changes of TBS, the sections 
were incubated with goat anti-rabbit 
polyclonal antibodies as secondary antibody 
at diluting of 1:200 for 30minutes. Sections 
were washed again in TBS and then 
incubated with subsliate chromogen solution 
for 2-8minutes. 
 
IHC scoring was based on DAKO Hercep 
test score, the score ranges from 0 to 3+. 
Scores equal or greater than 2+ was 
considered as over expression of C-erbB-2 
oncoprotein. 
Score O, negative; No staining is observed 
or membrane staining is observed in less 
than 10%of tumour cell. 
Score 1+, negative; Afaint or barely 
perceptible membrane staining is observed 
in more than 10%of the tumour cells. The 
cells are only stained in part of their 
membrane. 
Score 2+weak positive; weak to moderate 
complete membrane staining is observed in  
More than 10% of tumour cells. 
Score 3+strong positive; strong complete 
membrane staining is observed in more than 




Histological appraisal of the slides was done 
50% of the patients had poorly 
differentiated carcinoma and only 20% of 
this had over expression of C-erbB-2 
oncoprotein receptors. The age of the 
patients ranged from 50 to 86 years. Close 
to half of the patients 45% showed over 
expression of C-erbB-2 oncoprotein 
receptors Majority of the patients that had 
over expression had higher histology grades. 
Data is summarized in the table below 
 
Table 1. C-erbB-2Status distribution by 































X2 =4.41                          Df =2                      
P = 0.110 
 
No statistical significance was observed in 
the relation between histological grades and 




Its generally agreed documented that higher 
histological grades is associated with over 
expression of C-erbB-2 oncoprotein further 
studies showed an association with poor 
prognosis. The frequency of over expression 
has been shown to vary from 0-100% some 
of this has been attributed to difference in 
the material, reagents, and scoring system. 
This trend could be aided by development 
of certified reference materials for common 
IHC stains, development of reference 
methods, validation of commercial staining 
instruments and test systems. 
 
In this study the results are in accordance 
with those of Kuhn12 who studied 53 cases 
positive staining was in 6 out of 27(22%) 
well differentiated carcinoma, 8 out of 
East and Central African Journal of Surgery                                   http://www.bioline.org.br/js 
East and Central  African Journal of Surgery               Volume 13 Number 1 – March / April 2008. 
40
20(40%) moderately differentiated 
carcinoma, and 4 of 6(66%) of poorly 
differentiated carcinoma of the prostate (P = 
0.03, chi-square test for trend).16 Although 
in our study the result was statistically 
insignificant most of the patients 14 (77.8%) 
that were positive for over expression had 
higher histological grades Giving an 
indication that over expression could be 
associated with more aggressive disease.  
 
Conclusion and recommendation 
 
Immunohistochemistry which is cheap and 
easy to use can be used in our setting to 
analyse the level of C-erbB-2. Its important 
that long term follow up of the patients with 
over expression is needed to further 
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